Quantcast

Latest Oligodendroglioma Stories

2011-09-20 00:13:36

Study led by St. Jude Children´s Research Hospital scientists points to possible new treatment targets for diffuse intrinsic pontine gliomas; may tip the scales in the current debate about tumor biopsies The largest study ever of a rare childhood brain tumor found more than half the tumors carried extra copies of specific genes linked to cancer growth, according to research led by St. Jude Children's Research Hospital investigators. The findings identify possible new targets for...

2011-08-09 07:19:10

(Ivanhoe Newswire) "“ Scientists have completed a map of genetic mutations occurring in the second-most common form of brain cancer, oligodendroglioma. The findings appear to reveal the biological cause of the tumors. Oligodendroglioma accounts for up to 20 percent of brain cancers and more commonly occur in younger people and 30 to 45. To create the map, the scientists sequenced protein-coding genes in seven oligodendroglioma tissue samples, and focused attention on recurring mutations...

2011-08-05 12:08:45

Findings reveal cause of the tumors Johns Hopkins Kimmel Cancer Center scientists have completed a comprehensive map of genetic mutations occurring in the second-most common form of brain cancer, oligodendroglioma. The findings, reported in the Aug. 4 issue of Science, also appear to reveal the biological cause of the tumors, they say. To create the map, the scientists sequenced protein-coding genes in seven oligodendroglioma tissue samples, and focused attention on recurring mutations in two...

2011-06-06 00:30:00

CHICAGO, June 6, 2011 /PRNewswire/ -- Cell Therapeutics, Inc. ("CTI") (NASDAQ: CTICD and MTA: CTIC) announced encouraging interim results of a phase II clinical study of OPAXIO (paclitaxel poliglumex, PPX) combined with temozolomide ("TMZ") and radiotherapy ("RT") in patients with newly diagnosed high-grade malignant brain tumors (astrocytomas and glioblastomas). While not a randomized trial, treatment with OPAXIO, TMZ and RT resulted in a median progression free survival (PFS) of 13.5...

2011-06-03 12:26:56

Survival rates of wealthier patients and those younger than 70 with glioblastoma, the most common and aggressive malignant brain tumor, have improved since 2000, whereas rates for those living in poorer areas and older than 70 have remained stagnant, according to an abstract being presented at the American Society of Clinical Oncology annual meeting in Chicago by Thomas Jefferson University Hospital researchers on Saturday, June 4. (ABSTRACT #6089). The addition of concurrent and adjuvant...

2011-05-19 13:50:31

RTOG reports on the largest trial to-date for patients with newly diagnosed glioblastoma demonstrating the importance and feasibility of prospective molecular analysis of tumor tissue although finding that patients received no additional benefit from dose-intensive temozolomide as compared to standard adjuvant temozolomide after combined temozolomide and radiotherapy. The integration of tumor analysis with the clinical trial and international collaboration, major components of this...

2011-04-19 16:50:30

Findings show that damage to surrounding tissue may play role in determining high-grade glioma patients' long-term outcome Minimizing neurological side effects in patients with high-grade glioma from chemoradiation may result in improved patient survival, a new study from radiation oncologists at the Kimmel Cancer Center at Jefferson suggests. These findings were reported in the April issue of the British Journal of Cancer. The researchers found that the occurrence of early side effects, such...

2011-04-16 00:44:03

First ever medical device therapy indicated as an alternative to chemotherapy for cancer Novocure today announced that the U.S. Food and Drug Administration (FDA) approved the NovoTTF-100A System (NovoTTF) for the treatment of adult patients with glioblastoma multiforme (GBM) brain tumors, following tumor recurrence after receiving chemotherapy. The portable, wearable device delivers an anti-mitotic, anti-cancer therapy as patients maintain their normal daily activities. The NovoTTF is a...

2011-03-14 16:21:26

St. Jude Children's Research Hospital investigators use a novel model system to show how specific mutations can induce glioma formation in multiple regions of the brain and to begin studying patient response to a new generation of targeted therapies Mutations in three pathways important for suppressing tumors cooperate to launch glioblastoma, an aggressive brain tumor that strikes children and adults. But new research from St. Jude Children's Research Hospital scientists shows those changes...

2011-02-01 02:00:27

Scientists at Duke Cancer Institute have discovered that genetic mutations found in brain tumors can alter tumor metabolism. This work could help lead to new designs for anti-cancer drugs based on the unique properties of these tumors. "Malignant glioma appears to be at least two large subclasses of diseases "“ one that involves mutations in the IDH1 and IDH2 genes and one that doesn't," said Hai Yan, M.D., Ph.D., an associate professor in the Duke Department of Pathology who led a...


Word of the Day
call-note
  • The call or cry of a bird or other animal to its mate or its young.
'Call-note' is newer than 'bird-call,' which originally referred to 'an instrument for imitating the note of birds' but now also refers to 'the song or cry of a bird.'
Related